Aging and liver pathology: molecular and cell aspects
- 作者: Mesheriakova I.E1, Ilina A.R1,2, Linkova N.S1,3, Koroleva M.V3, Khavinson V.K.1,4
-
隶属关系:
- Saint Petersburg Bioregulation and Gerontology Institute
- Peter the Great Saint Petersburg Polytechnic University
- Academy of Postgraduate Education under Federal Scientific and Clinical Center for Specialized types Medical Assistance and Medical Technologies of the FMBA
- Pavlov Institute of Physiology Russian Academy of Sciences
- 期: 卷 31, 编号 6 (2020)
- 页面: 16-23
- 栏目: Articles
- URL: https://journals.eco-vector.com/0236-3054/article/view/114218
- DOI: https://doi.org/10.29296/25877305-2020-06-03
- ID: 114218
如何引用文章
详细
全文:
作者简介
I. Mesheriakova
Saint Petersburg Bioregulation and Gerontology Institute
Email: miayy@yandex.ru
A. Ilina
Saint Petersburg Bioregulation and Gerontology Institute; Peter the Great Saint Petersburg Polytechnic University
Email: miayy@yandex.ru
Institute of biomedical systems and biotechnologies
N. Linkova
Saint Petersburg Bioregulation and Gerontology Institute; Academy of Postgraduate Education under Federal Scientific and Clinical Center for Specialized types Medical Assistance and Medical Technologies of the FMBA
Email: miayy@yandex.ru
Doctor of Biological Sciences Moscow
M. Koroleva
Academy of Postgraduate Education under Federal Scientific and Clinical Center for Specialized types Medical Assistance and Medical Technologies of the FMBA
Email: miayy@yandex.ru
Candidate of Medical Sciences; Professor Moscow
V. Khavinson
Saint Petersburg Bioregulation and Gerontology Institute; Pavlov Institute of Physiology Russian Academy of Sciences
Email: miayy@yandex.ru
Corresponding Member of RAS Saint Petersburg
参考
- Schwabe R.F., Tabas I., Pajvani U.B. Mechanisms of Fibrosis Development in Nonalcoholic Steatohepatitis. Gastroenterology. 2020; pii: S0016-5085(20)30169- doi: 10.1053/j.gastro.2019.11.311
- Tajir K., Shimizu Y. Liver physiology and liver diseases in the elderly. World J Gastroenterol. 2013; 19 (5): 8459-67. doi: 10.3748/wjg.v19.i46.8459
- Kim I.H., Kisseleva T., Brenner D.A. Aging and liver disease. Curr Opin Gastroenterol. 2015; 31 (3): 184-91. doi: 10.1097/M0G.0000000000000176
- Schmucker D.L., Sanchez H. Liver regeneration and aging: A current perspective. CurrGerontol GeriatrRes. 2011; 2011: 526379. doi: 10.1155/2011/526379
- Basseri S., Austin R.C. Endoplasmic reticulum stress and lipid metabolism: mechanisms and therapeutic potential. Biochem Res Int. 2012; 2012: 841362. doi: 10.1155/2012/841362
- Gong Z., Tas E., Yakar S. et al. Hepatic lipid metabolism and non-alcoholic fatty liver disease in aging. Mol Cell Endocrinol. 2017; 455: 115-30. doi: 10.1016/j.mce.2016.12.022
- Schmucker D.L. Age-related changes in liver structure and function: Implications for disease? Exp Gerontol. 2005; 40 (8-9): 650-9. doi: 10.1016/j.exger.2005.06.009
- Schoenfelder K.P., Fox D.T. The expanding implications of polyploidy. J Cell Biol. 2015; 209 (4): 485-91. doi: 10.1083/jcb.201502016
- Celton-Morizur S., Merlen G., Couton D. et al. The insulin/Akt pathway controls a specific cell division program that leads to generation of binucleated tetraploid liver cells in rodents. J Clin Invest. 2009; 119 (7): 1880-7. doi: 10.1172/jci38677
- Banales J.M., Huebert R.C., Karlsen T. et al. Cholangiocyte pathobiology. Nat Rev Gastroenterol Hepatol. 2019; 16 (5): 69-281. doi: 10.1038/s41575-019-0125-y
- Jensen K., Marzioni M., Munshi K. et al. Autocrine regulation of biliary pathology by activated cholangiocytes. Am J Physiol Gastrointest Liver Physiol. 2012; 302 (5): G473-83. doi: 10.1152/ajpgi.00482.2011
- O’Hara S.P., Splinter P.L., Trussoni C.E. et al. The transcription factor ETS1 promotes apoptosis resistance of senescent cholangiocytes by epigenetically up-regulating the apoptosis suppressor BCL2L1. J Biol Chem. 2019; 294 (4): 18698-713. doi: 10.1074/jbc.RA119.010176
- Maeso-Diaz R., Ortega-Ribera M., Fernändez-Iglesias A. et al. Effects of aging on liver microcirculatory function and sinusoidal phenotype. Aging Cell. 2018; 17 (6): e12829. doi: 10.1111/acel.12829
- Mysore K.R., Leung D.H. Hepatitis B and C. Clin Liver Dis. 2018; 22 (4): 703-22. doi: 10.1016/j.cld.2018.06.002
- Beyoglu D., Idle J.R. The metabolomic window into hepatobiliary disease. J Hepatol. 2013; 59 (4): 842-58. doi: 10.1016/j.jhep.2013.05.030
- Fu S., Wu D., Jiang W. et al. Molecular Biomarkers in Drug-Induced Liver Injury: Challenges and Future Perspectives. Front Pharmacol. 2020; 10 :1667. doi: 10.3389/fphar.2019.01667
- Luedde T., Kaplowitz N., Schwabe R.F. Cell death and cell death responses in liver disease: mechanisms and clinical relevance. Gastroenterology. 2014; 147 (4): 765-83.e4. doi: 10.1053/j.gastro.2014.07.018
- Danjuma M.I., Sajid J., Fatima H. et al. Novel biomarkers for potential risk stratification of drug induced liver injury (DILI): A narrative perspective on current trends. Medicine (Baltimore). 2019; 98 (50): e18322. doi: 10.1097/MD.0000000000018322
- Church R.J., Watkins P.B. The transformation in biomarker detection and management of drug-induced liver injury. Liver Int. 2017; 37 (11): 1582-90. doi: 10.1111/liv.13441
- Ku N.O., Strnad P., Bantel H. et al. Keratins: Biomarkers and modulators of apoptotic and necrotic cell death in the liver. Hepatology. 2016; 64 (3): 966-6. doi: 10.1002/hep.28493
- An J., Kim J.W., Shim J.H. et al. Chronic hepatitis B infection and nonhepatocellular cancers: A hospital registry-based, case-control study. PLoS One. 2018; 13 (3): e0193232. doi: 10.1371/journal.pone.0193232
- Harrill A.H., Roach J., Fier I. et al. The effects of heparins on the liver: Application of mechanistic serum biomarkers in a randomized study in healthy volunteers. Clin Pharmacol Ther. 2012; 92 (2): 214-20. DOI: 10.1038/ clpt.2012.40
- Metushi I., Uetrecht J., Phillips E. Mechanism of isoniazid-induced hepatotoxicity: Then and now. Br J Clin Pharmacol. 2016; 81 (6): 1030-6. doi: 10.1038/clpt.2012.40
- Li S., Xue F., Zheng Y. et al. GSTM1 and GSTT1 null genotype increase the risk of hepatocellular carcinoma: evidence based on 46 studies. Cancer Cell Int. 2019; 19 (1): 76. doi: 10.1186/s12935-019-0792-3
- Park W.J., Kim S.Y., Kim Y.R. et al. Bortezomib alleviates drug-induced liver injury by regulating CYP2E1 gene transcription. Int J Mol Med. 2016; 37 (3): 613-22. doi: 10.3892/ijmm.2016.2461
- Li L., Li D., Heyward S. et al. Transcriptional regulation of CYP2B6 expression by hepatocyte nuclear factor 3ß in human liver cells. PLoS One. 2016; 11 (3): e0150587. doi: 10.1371/journal.pone.0150587
- Wang D., Lu R., Rempala G. et al. Ligand-free estrogen receptor a (ESR1) as master regulator for the expression of CYP3A4 and other cytochrome P450 enzymes in the human liver. Mol Pharmacol. 2019; 96 (4): 430-40. doi: 10.1124/mol.119.116897
- Gao Y., Cao Z., Yang X. et al. Proteomic analysis of acetaminophen-induced hepatotoxicity and identification of heme oxygenase 1 as a potential plasma biomarker of liver injury. Proteomics Clin Appl. 2017; 11 (1-2). doi: 10.1002/prca.201600123
- Bruschi F.V., Tardelli M., Herac M. et al. Metabolic regulation of hepatic PNPLA3 expression and severity of liver fibrosis in patients with NASH. Liver Int. 2020; 40 (5):1098-110. doi: 10.1111/liv.1440
- Annegowda V.M., Devi H.U., Rao K. et al. Immunohistochemical study of alpha-smooth muscle actin in odontogenic cysts and tumors. J Oral Maxillofac Pathol. 2018; 22 (2): 188-92. doi: 10.4103/jomfp.JOMFP_31_18
- Krützfeldt J., Rajewsky N., Braich R. et al. Silencing of microRNAs in vivo with «antagomirs». Nature. 2005; 438 (7068): 685-9. doi: 10.1038/nature04303
- Pawlak M., Lefebvre P., Staels B. Molecular mechanism of PPARa action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease. J Hepatol. 2015; 62 (3): 720-33. doi: 10.1016/j.jhep.2014.10.039
- Yu J., Peng J., Luan Z. et al. MicroRNAs as a novel tool in the diagnosis of liver lipid dysregulation and fatty liver disease. Molecules. 2019; 24 (2): pii: E230. doi: 10.3390/molecules24020230
- Sulaiman S.A., Muhsin N.I.A., Jamal R. Regulatory non-coding RNAs network in non-alcoholic fatty liver disease. Front Physiol. 2019; 10: 279. doi: 10.3389/fphys.2019.00279
- Sun C., Fan J.G., Qiao L. Potential epigenetic mechanism in non-alcoholic fatty liver disease. Int J Mol Sci. 2015; 16 (3): 5161-79. DOI: 10.3390/ ijms16035161
- Dadrich M., Nicolay N.H., Flechsig P. et al. Combined inhibition of TGFß and PDGF signaling attenuates radiation-induced pulmonary fibrosis. Oncoimmunology. 2016; 5 (5): e1123366. doi: 10.1080/2162402X.2015.1123366
- Noguchi S., Saito A., Nagase T. YAP/TAZ signaling as a molecular link between fibrosis and cancer. Int J Mol Sci. 2018; 19 (11): pii: e3674. doi: 10.3390/ijms19113674
- Dupont S. Role of YAP/TAZ in cell-matrix adhesion-mediated signalling and mechanotransduction. Exp Cell Res. 2016; 343 (1): 42-53. doi: 10.1016/j.yexcr.2015.10.034
- Tsuchida T., Friedman S.L. Mechanisms of hepatic stellate cell activation. Nat Rev Gastroenterol Hepatol. 2017; 14 (7): 397-411. doi: 10.1038/nrgastro.2017.38
- Zhu C., Kim K., Wang X. et al. Hepatocyte Notch activation induces liver fibrosis in nonalcoholic steatohepatitis. Sci Transl Med. 2018; 10 (468): eaat0344. doi: 10.1126/scitranslmed.aat0344